FDA Weighs Major Reform of Rare Disease Drug Approval! Greater Patient Voice, Clearer Regulatory Path for Drugmakers

The U.S. Food and Drug Administration (FDA) is launching a top-down comprehensive review to reassess how it handles the development and approval of rare disease drugs. On Wednesday, the FDA will announce the "Rare Disease Framework Initiative." The initiative aims to establish a new system that gives patients a greater voice in the regulatory process while providing drugmakers with a clearer regulatory pathway. The move comes after a turbulent year for the FDA. During the tenure of former FDA Commissioner Marty Makary, several rare disease drugs were unexpectedly rejected or had their approvals delayed. Makary left the FDA in May. The related incidents triggered a congressional investigation, prompted drugmakers to appeal to the White House, and drew opposition from patient groups. In interviews, senior FDA officials denied that the initiative was related to the previous controversies. They said it is part of the FDA's ongoing efforts to improve the rare disease drug development process, which has become increasingly important as rare disease drugs account for a growing share of FDA-approved drugs. Karim Mikhail, who heads the FDA's Center for Biologics Evaluation and Research, which oversees cell and gene therapies, said: "This is a genuine effort to change the way we review rare disease drugs." The new framework is intended to allow patients to provide input at earlier stages and at key points throughout the drug development and review process. It also seeks to provide drug developers with greater clarity and consistency in regulatory decisions. The FDA said in a statement that the framework should take into account the unique nature of rare diseases and what evidence can reasonably be obtained in such circumstances. Currently, patients typically express their views through advisory committees only after a drug enters the approval stage, clinical trials have concluded, and FDA reviewers have largely completed their work. At the same time, drugmakers may invest substantial resources in drug testing, only to end up in disagreement with regulators over what data the FDA requires for approval. Amy Comstock Rick, FDA Deputy Director for Rare Disease Strategy, said FDA officials should "always be clear with drug developers about the requirements" throughout the process. She added: "There should be no surprises." According to FDA data, about 30 million people in the United States suffer from rare diseases. As of 2025, only about 5% of the 7,000 to 10,000 identified rare diseases have FDA-approved treatments. The new initiative will officially launch with a meeting on October 28, where input will be heard from patient groups, disease advocacy organizations, industry, and other relevant parties. This effort is far broader in scope than an earlier initiative launched during Makary's tenurethe so-called "plausible mechanism" approval pathway. That initiative primarily targeted the rarest diseases, those affecting only a handful of patients. Michael Davis, director of the FDA's Center for Drug Evaluation and Research, said the new framework will not take a top-down approach but instead aims to incorporate input from rank-and-file FDA staff. He said: "We really want to move this initiative forward in the right way." FDA officials said in interviews that the initiative could ultimately result in formal guidance documents or regulations. Internally, the FDA aims to put forward preliminary recommendations by February of next year, though the timeline may be adjusted based on feedback received. Since Makary's departure, the FDA has not had a formal long-term leader. White House policy adviser Heidi Overton has been nominated to lead the FDA, and her nomination is still awaiting Senate consideration. Last month, Karim Mikhail and Michael Davis were announced as the official heads of their respective regulatory centers.